Achilles Therapeutics
ACHL
ACHL was delisted on the 20th of March, 2025.
27 hedge funds and large institutions have $18.1M invested in Achilles Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 8 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less funds holding
Funds holding: 32 → 27 (-5)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
38% less capital invested
Capital invested by funds: $29.4M → $18.1M (-$11.3M)
63% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
+$550K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$57.8K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$32K |
| 4 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$10.9K |
| 5 |
Two Sigma Investments
New York
|
+$8.51K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Stempoint Capital
New York
|
-$1.73M |
| 2 |
Renaissance Technologies
New York
|
-$284K |
| 3 |
FA
Forefront Analytics
West Conshohocken,
Pennsylvania
|
-$119K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$87.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$38.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Qube Research & Technologies (QRT)
London,
United Kingdom
| $59 | – | – | – |
|
|
SC
27
Stempoint Capital
New York
| – | -$1.73M | -1,385,750 | Closed |
|
|
FA
28
Forefront Analytics
West Conshohocken,
Pennsylvania
| – | -$119K | -95,445 | Closed |
|
29
Millennium Management
New York
| – | -$23.9K | -19,117 | Closed |
|
30
Vontobel Holding
Zurich,
Switzerland
| – | -$23.8K | -19,000 | Closed |
|
|
TSS
31
Two Sigma Securities
New York
| – | -$20.4K | -16,312 | Closed |
|
|
OIA
32
OneDigital Investment Advisors
Overland Park,
Kansas
| – | -$13.1K | -10,500 | Closed |
|
33
Bank of America
Charlotte,
North Carolina
| – | -$1.36K | -1,092 | Closed |
|
|
IGWM
34
ICA Group Wealth Management
Denver,
Colorado
| – | -$500 | -400 | Closed |
|
ACHL Hedge Fund Activity: Q2 2024 in Review
27 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2024, worth a combined $18.1M — down 38% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ACHL and 3 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was BML Capital Management, opening a new position worth an estimated $550K. The largest seller was Stempoint Capital, exiting entirely with an estimated $1.73M sold.
- 27 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2024, down from 32 in Q1 2024.
- Funds reported $18.1M of Achilles Therapeutics stock for Q2 2024, down 38% quarter-over-quarter.
- 3 funds opened new Achilles Therapeutics positions in Q2 2024 and 8 closed out, a net change of -5 holders.
- The largest Achilles Therapeutics buyer in Q2 2024 was BML Capital Management, an estimated $550K added.
- The largest Achilles Therapeutics seller in Q2 2024 was Stempoint Capital, an estimated $1.73M sold.
Based on aggregated 13F filings for Q2 2024.